← Back to headlines
Verrica Outlines $27.5M Financing to Extend Cash Runway into 2028
Verrica Pharmaceuticals has secured a $27.5 million nondilutive facility, aiming to extend its cash runway into 2028 as it anticipates top-line data from its COVE study by mid-2027.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
